Funds and ETFs Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange 11:30:50 2024-05-15 am EDT 5-day change 1st Jan Change
532.2 CHF +4.89% Intraday chart for Lonza Group AG +1.10% +50.47%
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
507.4 CHF
Average target price
576.9 CHF
Spread / Average Target
+13.69%
Consensus
  1. Stock Market
  2. Equities
  3. LONN Stock
  4. Funds and ETFs Lonza Group AG
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW